<DOC>
	<DOC>NCT02337322</DOC>
	<brief_summary>There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing 2 parallel groups, to compare the immunological reconstitution and the virological efficacy and safety of 2 different combinations of antiretroviral therapy given once a day (QD): abacavir plus lamivudine plus either dolutegravir, or darunavir-ritonavir during 96 weeks in advanced antiretroviral naïve HIV-1 infected patients with less than 100 CD4+ T-cells/mm3. Primary endpoint is the median increase in CD4+ T-cell count at 48 weeks after starting HAART.</brief_summary>
	<brief_title>Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>1. HIV patients &gt; 18 years old who provide signed and dated informed consent. 2. Male and female. 3. Chronic HIV infection. 4. Antiretroviral naïve. 5. Confirmed CD4+ T cell count below 100 cells/mm3 6. HLA B5701 negative patients. 1. Active opportunistic infections requiring parenteral treatment 2. Patients with cryptococcal meningitis treated with voriconazole 3. AIDSdefining cancers needing chemotherapy. 4. Female patients pregnant or breastfeeding. 5. Patients with documented history of allergy to sulfonamides. 6. Any contraindications to study drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Antiretroviral treatment</keyword>
	<keyword>HIV Advanced Disease</keyword>
	<keyword>AIDS</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>Darunavir</keyword>
</DOC>